Montelukast, a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist, and zileuton, a 5‐lipoxygenase inhibitor, are widely used in chronic inflammatory diseases such as asthma, where they provide a targeted means to reduce inflammation without broad immunosuppressive effects [8, 12]. The gene discussed is CYSLTR1; the disease is asthma.